Metabolic health monitoring platform Vively has raised $1.6 million in a Seed round as it rolls out its Continuous Glucose Monitoring (CGM) program to tackle pre-diabetes.
The round was led by Archangel Ventures with support from Bupa Ventures, the VC arm of not-for-profit private health insurer Bupa, and others.
Archangel previously led 2022’s $1.5 million pre-Seed round, three months after cofounder and CEO Tim Veron launched the platform with Michael Pang.
Vively combines real-time glucose monitoring with AI-driven insights and coaching to help users understand how their diet, sleep, stress, and activity impact their health and how to make small, measurable habit changes.
The cash injection coincides with the launch of the insurer-backed CGM program, which makes preventative health more accessible and practical, in partnership with Bupa. While CGM has been traditionally used for diabetes management, is now being offered to support early lifestyle intervention through a low-cost program.
“We’re building a future where people don’t wait to get sick before taking control of their health,” Veron said.
“This partnership with Bupa and the backing of our investors accelerates our mission to shift healthcare from reactive to preventative, giving people the tools to act on their metabolic health before it’s too late.”
He’s hoping the capital will help the company grow from $3 million to $10m in annualised revenue over the next 12-18 months.
Bupa APAC’s chief customer and transformation officer, Danielle Handley, said this funding and pilot is a strategic investment in preventative healthcare to improve health outcomes for their customers.
“Through this investment and collaborative pilot, we see huge potential in our partnership with Vively which shares our goal of enabling preventative healthcare that is more connected and customer centric,” she said.
Bupa members in the pilot receive a CGM device and app that monitors their glucose levels continuously. The data is analysed to provide tailored health insights and lifestyle recommendations, supported by Vively’s team of dieticians and health coaches.
Vively Health CEO, Tim Veron, said partnering with Bupa allows them to grow their footprint and shift healthcare from reactive to proactive.
“We believe that everyone deserves access to tools that can help improve their health outcomes, and this pilot is a major step towards achieving that goal. We are really excited about what we can achieve together as part of this program and beyond,” Tim said.
Interventions at the pre-diabetic stage can help prevent the onset of type 2 diabetes, while a sustained improvement in metabolic health also decreases the risk of other chronic conditions including obesity and heart disease.
Daily startup news and insights, delivered to your inbox.